Deshpande LM, Jones RN.
Bactericidal activity and synergy
studies of BAL9141, a novel
pyrrolidinone-3-ylidenemethyl cephem,
tested against streptococci,
enterococci and methicillin-resistant
staphylococci. Clin Microbiol Infect.
2003; 9(11): 1120–4.
Hujer AM, Bethel CR, Helfland MS,
Shapiro S, Page MGP, Bonomo RA. In
vitro activity of BAL9141 and
BAL0010078-001 against Escherichia
coli DH10B strains harboring blaSHV
mutants conferring ceftazidime (TAZ)
resistance. 43rd ICAAC 2003. Poster
C1-685.
Hujer AM, Bethel CR, Shapiro S,
Paterson DL, Page MGP, Bonomo RA. In
vitro activity of BAL9141, a broad
spectrum pyrrolidinone cephalosporin,
against Klebsiella pneumoniae
isolates possessing extended spectrum
beta-lactamases (ESBLs). 43rd ICAAC
2003. Poster F-542.
Luttringer O, Theil FP, Poulin P,
Schmitt-Hoffmann AH, Guentert TW,
Lave T. Physiologically Based
Pharmacokinetics (PBPK) Modeling of
Disposition of Epiroprim in Humans. J
Pham Sci 2003; 92: 1990-2007.
Roos B, Schmitt-Hoffmann A,
Schleimer M, Weidekamm E, Brown T,
Heep M, Nilsson LG. Safety and
Pharmacokinetics of BAL5788 in
Healthy Subjects with Normal or
Impaired Renal Function. 43rd ICAAC
2003. Poster A1-2358.
Schmitt-Hoffmann AH, Roos B, Heep
M, Weiderkamm E, Beglinger C.
Pharmacokinetics of BAL4815, a new
azole antifungal, after
administration of single ascending
oral doses of its pro-drug BAL8557.
43rd ICAAC 2003. Poster A1-3047.
Thurnheer T, Gmur R, Shapiro S,
Guggenheim B. Mass transport of
macromolecules within an in vitro
model of supragingival plaque.
Applied and Environmental
Microbiology 2003; 69(3):
1702–1709.
Wilkinson AS, Bryant PK, Meroueh
SO, Page MGP, Mobashery S,
Christopher WA. Dynamic Structure for
the Acyl-Enzyme Species of the
Antibiotic Aztreonam with the
Citrobacter freundii Beta-Lactamase
Revealed by Infrared Spectroscopy and
Molecular Dynamics Simulations.
Biochemistry 2003; 42 (7):
1950–1957.